Resources from the same session
402O - Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
Presenter: Danyun Ruan
Session: Proffered Paper session: Head and neck cancers
Resources:
Abstract
Slides
Webcast
403O - Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
Presenter: Wen Feng Fang
Session: Proffered Paper session: Head and neck cancers
Resources:
Abstract
Q&A and discussion
Session: Proffered Paper session: Head and neck cancers
Resources:
Webcast
404O - A phase III prospective randomised trial of two- weekly TPF(Taxane/Platinum/5FU) vs three weekly TPF as induction chemotherapy in locally advanced squamous cell carcinoma of head and neck: A preliminary analysis
Presenter: Animesh Gupta
Session: Proffered Paper session: Head and neck cancers
Resources:
Abstract
Slides
Webcast
405O - Accuracy of plasma Epstein-Barr virus (EBV) DNA for disease surveillance in endemic nasopharyngeal carcinoma (NPC): Analysis of a real-world database (RWD)
Presenter: Melvin Lee Kiang Chua
Session: Proffered Paper session: Head and neck cancers
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Head and neck cancers
Resources:
Webcast